l General Information |
Product Name | Mirabegron |
General description | Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM. |
Synonym | YM 178; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide |
Purity | ≥99.0%(HPLC) | CAS Number | 223673-61-8 |
Formula | C21H24N4O2S | Molecular Weight | 396.509 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or off-white Solid |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | ~5mg/mL |
Water | Very slightly soluble |
l Biological Information |
Biochem/Physiol
Actions | Mirabegron is an orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
